MedPath

Warfarin

Generic Name
Warfarin
Brand Names
Coumadin, Jantoven
Drug Type
Small Molecule
Chemical Formula
C19H16O4
CAS Number
81-81-2
Unique Ingredient Identifier
5Q7ZVV76EI
Background

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

Indication

Indicated for:

1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.

2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.

3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.

4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.

Off-label uses include:

1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.

Associated Conditions
Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)

Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data

Completed
Conditions
Venous Thromboembolism
Interventions
First Posted Date
2021-02-03
Last Posted Date
2023-07-27
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
19002
Registration Number
NCT04736719
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data

Completed
Conditions
Venous Thromboembolism
Interventions
First Posted Date
2021-02-03
Last Posted Date
2023-07-28
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
78605
Registration Number
NCT04736420
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data

Completed
Conditions
Venous Thromboembolism
Interventions
First Posted Date
2021-02-03
Last Posted Date
2023-08-01
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
5350
Registration Number
NCT04735523
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Clinical Trial to Investigate Safety and Efficacy of Edoxaban in Patients With CTEPH (KABUKI)

First Posted Date
2021-01-29
Last Posted Date
2023-10-05
Lead Sponsor
Kyushu University
Target Recruit Count
74
Registration Number
NCT04730037
Locations
🇯🇵

Kyushu University Hospital, Fukuoka, Japan

STOPping Anticoagulation for Isolated or Incidental Subsegmental Pulmonary Embolism

Phase 3
Conditions
Subsegmental Pulmonary Embolism Nos
Interventions
Other: No treatment
Drug: direct oral anticoagulants
Drug: Low molecular weight heparin
First Posted Date
2021-01-27
Last Posted Date
2021-09-29
Lead Sponsor
University of Birmingham
Target Recruit Count
1466
Registration Number
NCT04727437
Locations
🇬🇧

Surrey & Sussex Healthcare NHS Trust, Redhill, United Kingdom

A Drug Interaction Study of Danicopan

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Ethinyl Estradiol/Norethindrone
First Posted Date
2021-01-14
Last Posted Date
2021-01-14
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
52
Registration Number
NCT04709094
Locations
🇺🇸

Clinical Study Site, Tempe, Arizona, United States

A Study in Healthy People to Test Whether BI 730357 Influences the Amount of Caffeine, Warfarin, Omeprazole, and Midazolam in the Blood

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Percoffedrinol®
Drug: Antra MUPS®
Drug: Midazolam-ratiopharm®
First Posted Date
2020-12-22
Last Posted Date
2023-08-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
16
Registration Number
NCT04679948
Locations
🇩🇪

Humanpharmakologisches Zentrum Biberach, Biberach, Germany

NOACs in Oral and Maxillofacial Surgery: Impact on Post-operative Complications

Completed
Conditions
Anticoagulant-induced Bleeding
Surgery, Oral
Hemorrhage
Oral Surgical Procedures
Postoperative Complications
Anticoagulants Causing Adverse Effects in Therapeutic Use
Interventions
First Posted Date
2020-12-10
Last Posted Date
2024-01-26
Lead Sponsor
Malmö University
Target Recruit Count
216
Registration Number
NCT04662515
Locations
🇸🇪

Skåne University Hospital, Helsingborg, Sweden

🇸🇪

Department of Oral and Maxillofacial Surgery and Oral Medicine, Faculty of Odontology, Malmö University, Malmö, Sweden

Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy(ESAWAAPT)

Phase 4
Completed
Conditions
Cirrhosis
Splenectomy; Status
Venous Thrombosis
Hypertension, Portal
Interventions
First Posted Date
2020-11-27
Last Posted Date
2025-03-21
Lead Sponsor
Northern Jiangsu People's Hospital
Target Recruit Count
120
Registration Number
NCT04645550
Locations
🇨🇳

Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu, China

Anticoagulation in Patients With Venous Thromboembolism and Cancer

Active, not recruiting
Conditions
Neoplasms
Embolism
Interventions
First Posted Date
2020-11-06
Last Posted Date
2025-05-06
Lead Sponsor
Pfizer
Target Recruit Count
1
Registration Number
NCT04618913
Locations
🇬🇧

Pfizer Investigational Site, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath